Yvonne Y Chen, MD
Nephrology · Oakland
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 14
- 2 carriers
- Office
- 1
- Since medical school
- 31 years
- Albert Einstein College of Medicine of Yeshiva University, 1995
Offices
1 location · West Coast Kidney · 56 clinicians in this group
Hospitals listed: 052721 · 552600 · Alameda Hospital · Alta Bates Summit Medical Center · Alta Bates Summit Medical Center - Alta Bates Camp · Eden Medical Center · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
14 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chen’s office at (510) 451-0996 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
14 of 14 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A70467 · Current
Licensed to practise in California · since 1999 · expires 2027-10-31 · Albert Einstein College of Medicine of Yeshiva University.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Nephrology
Hospitals they work in
5 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Alameda HospitalAlameda, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency departmentPart of Alameda Health System, which runs 4 hospitalsPatients rate it 3 of 5 · 64% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
- Alta Bates Summit Medical CenterOakland, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Death rate among surgical inpatients with serious treatable complications: 130.09 (87.72 to 172.46) · 109 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.274, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.227, Oct 2024 – Sep 2025
- Alta Bates Summit Medical Center - Alta Bates CampBerkeley, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.298, Oct 2024 – Sep 2025
- Eden Medical CenterCastro Valley, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 75% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.122, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Alameda Hospital
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 0 better, 3 the same, 0 worse of 3 measures. Readmissions: 0 better, 4 the same, 0 worse of 4 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.03 (0 to 2.12) · 119 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.89 (0.45 to 1.32) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.9 · 35 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.3 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.5 · 210 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.7 · 91 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 532 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.42) · 1,887 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.04 to 0.47) · 1,916 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.37 (0.77 to 5.96) · 80 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.3 (0.58 to 4.02) · 85 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.74 (0.22 to 3.26) · 38 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.3 (0 to 1.23) · 1,359 cases | No different | Jul 2022 – Jun 2024 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.9 · 98 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -2.4 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -3.6 · 242 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.5 · 244 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 40 cases | None | Jul 2023 – Jun 2025 |
What patients said (319 patients answered, 19% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 69% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 66% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 65% |
| Nurses "always" listened carefully | 65% |
| Nurses "always" treated them with courtesy and respect | 78% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 64% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
See every measure and the patient survey for Alta Bates Summit Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 4 better, 3 the same, 0 worse of 7 measures. Readmissions: 3 better, 6 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 130.09 (87.72 to 172.46) · 109 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.274 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.227 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0.06 to 1.94) · 1,209 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.88 (0.6 to 1.16) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.9 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.8 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 447 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.7 · 341 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.2 · 381 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 2,811 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.31) · 7,167 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,659 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.93 (0.92 to 4.94) · 1,668 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.25 (0 to 2.75) · 580 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.67 (1.19 to 4.15) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.17 (0.33 to 12.02) · 633 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 8.11 (4.67 to 11.55) · 619 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.07) · 309 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.39 (0 to 0.96) · 6,085 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.8 · 217 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.724 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.425 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.716 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 12.7 · 416 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 606 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -30.4 · 359 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -31.8 · 555 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -14.4 · 358 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16 · 382 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.1 (3.2 to 8.2) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.8 (7.3 to 16) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.5 · 232 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.9 · 56 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 152 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.8 (11.1 to 20) · 251 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 579 cases | No different | Jan 2024 – Dec 2024 |
What patients said (535 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Alta Bates Summit Medical Center - Alta Bates Camp
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 6 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.298 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.18 (0.16 to 2.2) · 730 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.51 to 1.23) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 188.12 (132.31 to 243.94) · 50 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 50 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 189 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.6 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 103 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 1,585 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 3,929 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.31 (0.11 to 0.51) · 3,954 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.15 (0.95 to 5.36) · 754 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.62 (0 to 3.33) · 325 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.99 (0.39 to 3.59) · 717 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.85 (2.27 to 19.44) · 326 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.79 (1.08 to 8.49) · 302 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.68 (0.19 to 3.18) · 184 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.17 (0 to 0.88) · 3,240 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 161 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.207 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.48 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.785 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.4 · 243 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -58.2 · 194 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -12.3 · 177 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 209 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.8 to 7.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.2 (9.4 to 15.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.8 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.2 · 81 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.4 (10 to 18.1) · 315 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.2) · 137 cases | No different | Jan 2024 – Dec 2024 |
What patients said (449 patients answered, 15% of those asked)
| Cleanliness | 2 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 62% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 53% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 58% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 66% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 38% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
See every measure and the patient survey for Eden Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 7 the same, 0 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.122 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.88 (0 to 1.89) · 819 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.46 to 1.16) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 137.41 (92.94 to 181.88) · 70 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.4 · 78 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.7 · 38 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.1 · 207 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.6 · 359 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 355 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 1,714 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.17 (0 to 0.39) · 4,697 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.3 (0.1 to 0.5) · 4,676 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.69 (0.53 to 4.85) · 860 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.56 (0 to 3.24) · 251 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.75 (1.17 to 4.32) · 818 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.76 (0 to 15.78) · 261 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.09 (2.08 to 10.1) · 242 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.64 (0.16 to 3.12) · 233 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.85) · 4,132 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 60 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.431 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.292 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.307 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.61 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 258 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 22.6 · 225 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 2.4 · 367 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.9 · 390 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 58 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 88 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.9 (9.6 to 17.4) · 68 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.1) · 205 cases | No different | Jan 2024 – Dec 2024 |
What patients said (431 patients answered, 17% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 58% |
| "YES", patients would definitely recommend the hospital | 75% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$311,397
Medicare paid this office $311,397 for 611 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Dialysis services, 4 or more physician visits per month (20 years or older) | 24 | $67,012 | $316 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 223 | $51,191 | $104 |
| Return visit (30+ min) | 234 | $40,185 | $98 |
| Long return visit (40+ min) | 137 | $29,001 | $134 |
| Home dialysis services per month (20 years or older) | 11 | $26,968 | $254 |
See all 16 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 24 | $67,012 | $316 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 223 | $51,191 | $104 |
| Return visit (30+ min) | 234 | $40,185 | $98 |
| Long return visit (40+ min) | 137 | $29,001 | $134 |
| Home dialysis services per month (20 years or older) | 11 | $26,968 | $254 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 156 | $21,311 | $69 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 126 | $20,499 | $151 |
| Critical care, first 30-74 minutes | 43 | $9,795 | $178 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 272 | $7,745 | $14 |
| Transitional care management services for problem of high complexity | 19 | $6,239 | $271 |
| New patient visit (60+ min) | 33 | $6,139 | $186 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 13 | $4,085 | $58 |
| Hemodialysis procedure with physician evaluation | 27 | $2,626 | $63 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 13 | $1,932 | $45 |
| Short return visit (20+ min) | 18 | $1,628 | $81 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 11 | $479 | $44 |
Who their Medicare patients are
611 Original Medicare patients in 2024. Average age 76 · Under 65 10% · 85 and older 23% · Women 48% · Also on Medicaid 73% · Health risk score 3.75. At or below the middle of the specialty; the typical nephrology clinician is at 4.01.
Conditions among them: High blood pressure 75% · Chronic kidney disease 75% · Diabetes 65% · Heart failure 50% · Coronary heart disease 42% · Atrial fibrillation 37% · COPD 25% · Depression 22% · Dementia 20% · Stroke 19% · Cancer 16%.
The office billed $856,966, Medicare allowed $417,508 and paid $311,397; for 2,812 services of 26 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 611 | 2,812 | 76 | 3.75 | $856,966 | $311,397 |
| 2023 | 613 | 2,409 | 76 | 3.93 | $869,244 | $315,754 |
| 2022 | 603 | 2,209 | 76 | 3.50 | $868,235 | $297,285 |
| 2021 | 590 | 2,332 | 76 | 3.73 | $896,161 | $346,400 |
| 2020 | 549 | 2,208 | 76 | 3.96 | $805,784 | $307,339 |
| 2019 | 654 | 2,591 | 75 | 3.97 | $883,926 | $331,150 |
| 2018 | 609 | 2,470 | 76 | 3.89 | $847,958 | $312,789 |
| 2017 | 587 | 4,086 | 75 | 3.99 | $868,281 | $321,795 |
| 2016 | 561 | 5,705 | 75 | 3.62 | $807,837 | $312,257 |
| 2015 | 540 | 5,080 | 75 | 3.63 | $795,744 | $307,507 |
| 2014 | 481 | 4,811 | 75 | 3.67 | $726,657 | $275,792 |
| 2013 | 487 | 5,350 | 74 | 4.02 | $687,192 | $265,556 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 11 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 31 | $78,514 | $322 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 223 | $57,067 | $106 |
| Return visit (30+ min) | 212 | $34,952 | $85 |
| Long return visit (40+ min) | 162 | $34,764 | $112 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 186 | $25,913 | $72 |
| Home dialysis services per month (20 years or older) | 11 | $24,108 | $262 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 122 | $20,161 | $155 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 11 | $11,860 | $264 |
| New patient visit (60+ min) | 41 | $7,567 | $185 |
| Critical care, first 30-74 minutes | 33 | $7,253 | $177 |
| Hemodialysis procedure with physician evaluation | 42 | $5,101 | $65 |
2022: 13 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 33 | $94,710 | $321 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 189 | $36,801 | $91 |
| Long return visit (40+ min) | 160 | $30,731 | $106 |
| Return visit (30+ min) | 219 | $27,812 | $75 |
| Home dialysis services per month (20 years or older) | 11 | $24,495 | $238 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 111 | $19,606 | $174 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 166 | $19,358 | $63 |
| New patient visit (60+ min) | 67 | $10,336 | $154 |
| Critical care, first 30-74 minutes | 37 | $9,725 | $187 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 14 | $8,859 | $268 |
| Hemodialysis procedure with physician evaluation | 46 | $4,638 | $64 |
| Transitional care management services for problem of high complexity | 16 | $3,765 | $198 |
| Short return visit (20+ min) | 12 | $669 | $51 |
2021: 12 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 37 | $107,874 | $325 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 237 | $53,149 | $93 |
| Long return visit (40+ min) | 143 | $38,905 | $151 |
| Return visit (30+ min) | 192 | $32,685 | $101 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 140 | $27,202 | $177 |
| Home dialysis services per month (20 years or older) | 19 | $21,978 | $256 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 158 | $18,020 | $65 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 12 | $12,591 | $268 |
| Critical care, first 30-74 minutes | 34 | $9,615 | $192 |
| New patient visit (60+ min) | 43 | $8,223 | $191 |
| Transitional care management services for problem of high complexity | 19 | $5,126 | $270 |
| Hemodialysis procedure with physician evaluation | 49 | $4,963 | $65 |
2020: 12 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 43 | $110,420 | $264 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 191 | $41,251 | $94 |
| Home dialysis services per month (20 years or older) | 14 | $29,073 | $217 |
| Long return visit (40+ min) | 121 | $27,642 | $124 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 114 | $23,468 | $183 |
| Return visit (30+ min) | 182 | $23,083 | $79 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 22 | $15,766 | $222 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 134 | $14,499 | $65 |
| Hemodialysis procedure with physician evaluation | 54 | $5,246 | $67 |
| Telephone medical discussion with physician, 21-30 minutes | 52 | $4,822 | $91 |
| New patient visit (60+ min) | 28 | $4,052 | $145 |
| Injection of drug or substance under skin or into muscle | 11 | $421 | $11 |
2019: 12 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 63 | $118,121 | $255 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 215 | $41,618 | $91 |
| Return visit (30+ min) | 214 | $28,974 | $82 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 146 | $28,174 | $174 |
| Home dialysis services per month (20 years or older) | 18 | $27,790 | $204 |
| Long return visit (40+ min) | 123 | $26,245 | $123 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 208 | $24,509 | $64 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 25 | $12,432 | $211 |
| Hemodialysis procedure with physician evaluation | 76 | $7,695 | $64 |
| New patient visit (60+ min) | 29 | $4,734 | $163 |
| Critical care, first 30-74 minutes | 12 | $2,334 | $194 |
| Injection of drug or substance under skin or into muscle | 18 | $1,190 | $14 |
2018: 13 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 53 | $124,950 | $252 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 171 | $35,111 | $92 |
| Return visit (30+ min) | 223 | $31,846 | $80 |
| Home dialysis services per month (20 years or older) | 14 | $24,219 | $192 |
| Long return visit (40+ min) | 104 | $20,176 | $118 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 177 | $19,081 | $61 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 92 | $17,992 | $175 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 23 | $10,564 | $211 |
| Hemodialysis procedure with physician evaluation | 67 | $8,602 | $64 |
| New patient visit (60+ min) | 29 | $4,851 | $167 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 28 | $3,629 | $117 |
| Critical care, first 30-74 minutes | 14 | $2,912 | $194 |
| Injection of drug or substance under skin or into muscle | 25 | $2,137 | $19 |
2017: 14 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 56 | $114,173 | $247 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 177 | $37,198 | $91 |
| Return visit (30+ min) | 225 | $30,884 | $78 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 180 | $22,203 | $62 |
| Home dialysis services per month (20 years or older) | 11 | $21,160 | $205 |
| Long return visit (40+ min) | 93 | $19,299 | $122 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 98 | $18,322 | $171 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 25 | $14,241 | None |
| Hemodialysis procedure with physician evaluation | 85 | $12,208 | $63 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 17 | $8,783 | $209 |
| New patient visit (60+ min) | 30 | $4,496 | $150 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 33 | $3,882 | $111 |
| Injection of drug or substance under skin or into muscle | 29 | $3,532 | $25 |
| Dialysis procedure including 1 evaluation | 13 | $2,356 | $76 |
2016: 14 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 45 | $107,143 | $243 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 175 | $35,010 | $88 |
| Return visit (30+ min) | 208 | $30,932 | $80 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 30 | $29,162 | None |
| Home dialysis services per month (20 years or older) | 11 | $22,074 | $204 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 177 | $18,800 | $61 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 92 | $17,722 | $167 |
| Long return visit (40+ min) | 74 | $13,374 | $114 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 25 | $10,866 | $209 |
| Hemodialysis procedure with physician evaluation | 57 | $6,681 | $62 |
| New patient visit (60+ min) | 43 | $6,198 | $144 |
| Injection of drug or substance under skin or into muscle | 30 | $5,073 | $24 |
| Critical care, first 30-74 minutes | 12 | $2,271 | $189 |
| Dialysis services, per day, less than full month service (20 years or older) | 15 | $1,747 | $7 |
2015: 13 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 54 | $112,706 | $243 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 157 | $33,401 | $89 |
| Return visit (30+ min) | 213 | $29,792 | $79 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 32 | $23,331 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 170 | $22,471 | $62 |
| Home dialysis services per month (20 years or older) | 11 | $21,659 | $204 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 86 | $16,813 | $173 |
| Hemodialysis procedure with physician evaluation | 77 | $9,280 | $62 |
| Long return visit (40+ min) | 43 | $8,023 | $118 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 27 | $7,290 | $203 |
| New patient visit (60+ min) | 34 | $5,641 | $166 |
| Injection of drug or substance under skin or into muscle | 31 | $4,001 | $23 |
| Critical care, first 30-74 minutes | 16 | $3,419 | $190 |
2014: 14 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 50 | $104,269 | $245 |
| Return visit (30+ min) | 184 | $28,222 | $80 |
| Home dialysis services per month (20 years or older) | 13 | $26,287 | $204 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 124 | $23,573 | $89 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 33 | $22,539 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 145 | $17,515 | $62 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 74 | $14,137 | $172 |
| Hemodialysis procedure with physician evaluation | 63 | $7,620 | $62 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 20 | $5,527 | $205 |
| Long return visit (40+ min) | 38 | $5,011 | $117 |
| Critical care, first 30-74 minutes | 19 | $3,760 | $188 |
| Injection of drug or substance under skin or into muscle | 33 | $3,626 | $22 |
| New patient visit (60+ min) | 19 | $2,942 | $155 |
| New patient visit (45+ min) | 20 | $1,948 | $97 |
2013: 19 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 54 | $96,264 | $241 |
| Return visit (30+ min) | 179 | $30,440 | $81 |
| Home dialysis services per month (20 years or older) | 15 | $24,153 | $205 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 34 | $22,833 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 154 | $19,052 | $60 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 104 | $16,776 | $87 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 62 | $11,917 | $168 |
| Hemodialysis procedure with physician evaluation | 76 | $9,385 | $61 |
| Injection of drug or substance under skin or into muscle | 35 | $4,309 | $23 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 19 | $4,126 | $196 |
| New patient visit (60+ min) | 23 | $3,619 | $157 |
| Long return visit (40+ min) | 27 | $3,588 | $112 |
| Dialysis services, per day, less than full month service (20 years or older) | 19 | $3,280 | $7 |
| New patient visit (45+ min) | 21 | $2,869 | $137 |
| Dialysis procedure including 1 evaluation | 12 | $2,593 | $74 |
| Critical care, first 30-74 minutes | 11 | $2,409 | $185 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 17 | $1,956 | $115 |
| Short return visit (20+ min) | 21 | $1,386 | $60 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 11 | $395 | $33 |
Medicaid work
$41,375 in 2024
Medicaid paid $41,375 for 967 billed services this clinician did in 2024, up to 49 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 413 | $19,168 |
| Long return visit (40+ min) | 209 | $7,054 |
| Return visit (30+ min) | 140 | $5,914 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 138 | $3,950 |
| 1ST HOSP IP/OBS HIGH 75 | 43 | $2,682 |
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 24 | $2,607 |
| 2024 | 967 | 6 | 49 | $41,375 |
| 2023 | 1,270 | 6 | 31 | $59,673 |
| 2022 | 1,152 | 7 | 35 | $35,073 |
| 2021 | 2,603 | 9 | 34 | $33,686 |
| 2020 | 5,176 | 9 | 42 | $43,652 |
| 2019 | 5,870 | 10 | 49 | $41,634 |
| 2018 | 5,162 | 11 | 50 | $42,865 |
See the largest Medicaid services in earlier years
2023
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 402 | $19,271 |
| Long return visit (40+ min) | 280 | $11,983 |
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 69 | $8,336 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 269 | $8,317 |
| Return visit (30+ min) | 196 | $7,744 |
| 1ST HOSP IP/OBS HIGH 75 | 54 | $4,023 |
2022
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 352 | $11,743 |
| Long return visit (40+ min) | 229 | $7,246 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 190 | $5,071 |
| Return visit (30+ min) | 214 | $4,419 |
| 1ST HOSP IP/OBS HIGH 75 | 43 | $3,503 |
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 107 | $2,895 |
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 17 | $195 |
2021
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 265 | $10,897 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 499 | $9,406 |
| Long return visit (40+ min) | 245 | $4,577 |
| Return visit (30+ min) | 231 | $4,317 |
| 1ST HOSP IP/OBS HIGH 75 | 52 | $2,240 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 126 | $2,139 |
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 16 | $109 |
| UNLISTED DIALYSIS PROCEDURE INPATIENT/OUTPATIENT | 1,064 | $0 |
| Iron sucrose injection | 105 | $0 |
2020
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 463 | $20,557 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 414 | $11,339 |
| Return visit (30+ min) | 215 | $3,898 |
| 1ST HOSP IP/OBS HIGH 75 | 59 | $3,065 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 151 | $2,768 |
| Long return visit (40+ min) | 164 | $1,917 |
| Iron sucrose injection | 486 | $106 |
| UNLISTED DIALYSIS PROCEDURE INPATIENT/OUTPATIENT | 2,984 | $0 |
| Injection, doxercalciferol, 1 mcg | 240 | $0 |
2019
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 508 | $20,317 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 315 | $6,073 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 262 | $4,477 |
| Long return visit (40+ min) | 179 | $3,969 |
| Return visit (30+ min) | 249 | $3,946 |
| 1ST HOSP IP/OBS HIGH 75 | 66 | $1,897 |
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 48 | $956 |
| UNLISTED DIALYSIS PROCEDURE INPATIENT/OUTPATIENT | 3,079 | $0 |
| Injection, doxercalciferol, 1 mcg | 730 | $0 |
| Iron sucrose injection | 434 | $0 |
2018
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 548 | $23,128 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 295 | $7,552 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 259 | $4,629 |
| Long return visit (40+ min) | 157 | $3,398 |
| Return visit (30+ min) | 277 | $2,938 |
| 1ST HOSP IP/OBS HIGH 75 | 15 | $1,220 |
| Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use | 14 | $0 |
| UNLISTED DIALYSIS PROCEDURE INPATIENT/OUTPATIENT | 3,004 | $0 |
| Administration of influenza virus vaccine | 14 | $0 |
| Injection, doxercalciferol, 1 mcg | 234 | $0 |
| Iron sucrose injection | 345 | $0 |
Drugs they prescribed that Part D paid
$1,105,346
Pharmacies billed $1,105,346 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 3,022) in 2024. At or below the middle of the specialty; the typical nephrology clinician is at 0%.
1,904 generic and 1,095 brand-name prescriptions · $1,105,346 in drug cost · 47 antibiotic prescriptions to 22 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Jardiance | 376 | $309,406 | $823 |
| Farxiga | 164 | $143,438 | $875 |
| Ozempic | 114 | $110,390 | $968 |
| Procrit | 97 | $71,256 | $735 |
| Xphozah | 24 | $67,659 | $2,819 |
See all 57 drugs
| Jardiance | 376 | $309,406 | $823 |
| Farxiga | 164 | $143,438 | $875 |
| Ozempic | 114 | $110,390 | $968 |
| Procrit | 97 | $71,256 | $735 |
| Xphozah | 24 | $67,659 | $2,819 |
| Kerendia | 57 | $53,772 | $943 |
| Veltassa | 37 | $51,046 | $1,380 |
| Rayaldee | 22 | $26,090 | $1,186 |
| Januvia | 18 | $21,920 | $1,218 |
| Rybelsus | 22 | $21,653 | $984 |
| Sevelamer Carbonate | 48 | $17,202 | $358 |
| Tradjenta | 12 | $14,028 | $1,169 |
| Lokelma | 18 | $13,950 | $775 |
| Invokana | 16 | $13,596 | $850 |
| Dapagliflozin | 19 | $11,184 | $589 |
| Retacrit | 16 | $8,258 | $516 |
| Cinacalcet | 15 | $3,855 | $257 |
| Febuxostat | 47 | $3,759 | $80 |
| Nebivolol | 29 | $3,294 | $114 |
| Clonidine | 23 | $2,110 | $92 |
| Calcium Acetate | 27 | $1,981 | $73 |
| Carvedilol | 212 | $1,222 | $6 |
| Losartan | 161 | $1,091 | $7 |
| Colchicine | 19 | $1,018 | $54 |
| Valsartan | 21 | $915 | $44 |
| Amlodipine Besylate | 212 | $878 | $4 |
| Allopurinol | 91 | $653 | $7 |
| Bumetanide | 11 | $652 | $59 |
| Olmesartan Medoxomil | 51 | $558 | $11 |
| Tamsulosin | 37 | $522 | $14 |
| Furosemide | 115 | $486 | $4 |
| Rosuvastatin | 39 | $456 | $12 |
| Metolazone | 12 | $440 | $37 |
| Hydralazine | 37 | $392 | $11 |
| Metformin | 59 | $381 | $6 |
| Atorvastatin | 70 | $320 | $5 |
| Clonidine | 22 | $290 | $13 |
| Isosorbide Mononitrate Er | 17 | $277 | $16 |
| Spironolactone | 11 | $240 | $22 |
| Nifedipine Er | 16 | $233 | $15 |
| Pantoprazole | 22 | $225 | $10 |
| Potassium Chloride | 25 | $216 | $9 |
| Nitrofurantoin Mono-Macro | 13 | $171 | $13 |
| Hydroxyzine | 15 | $150 | $10 |
| Calcitriol | 14 | $147 | $10 |
| Doxazosin Mesylate | 17 | $135 | $8 |
| Atenolol | 36 | $109 | $3 |
| Triamterene-Hydrochlorothiazid | 25 | $107 | $4 |
| Ciprofloxacin | 19 | $100 | $5 |
| Irbesartan | 11 | $76 | $7 |
| Lisinopril | 20 | $67 | $3 |
| Metoprolol | 15 | $64 | $4 |
| Benazepril | 16 | $61 | $4 |
| Hydrochlorothiazide | 35 | $61 | $2 |
| Metformin Hcl Er | 15 | $45 | $3 |
| Prednisone | 16 | $35 | $2 |
| Insulin | 13 | $12 | $1 |
Year by year
| 2024 | 3,022 | 336 | 0% (0) | 36% | $1,105,346 |
| 2023 | 2,976 | 333 | None | 30% | $1,052,725 |
| 2022 | 2,704 | 293 | 0% (0) | None | $840,335 |
| 2021 | 2,640 | 283 | None | 25% | $775,598 |
| 2020 | 2,705 | 268 | 0% (0) | 22% | $543,923 |
| 2019 | 2,775 | 285 | 0% (0) | 24% | $523,701 |
| 2018 | 2,965 | 267 | 0% (0) | 25% | $878,017 |
| 2017 | 2,780 | 267 | None | 31% | $626,889 |
| 2016 | 2,530 | 267 | None | 32% | $493,895 |
| 2015 | 2,358 | 245 | None | 35% | $416,154 |
| 2014 | 2,561 | 247 | 1% (13) | 34% | $406,497 |
| 2013 | 2,707 | 242 | None | None | $466,078 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 55 drugs
| Farxiga | 194 | $193,833 | $999 |
| Jardiance | 118 | $139,973 | $1,186 |
| Procrit | 98 | $97,393 | $994 |
| Kerendia | 72 | $74,460 | $1,034 |
| Rayaldee | 50 | $66,427 | $1,329 |
| Veltassa | 42 | $55,742 | $1,327 |
| Ozempic | 43 | $45,920 | $1,068 |
| Lokelma | 36 | $33,815 | $939 |
| Retacrit | 68 | $30,875 | $454 |
| Januvia | 26 | $28,615 | $1,101 |
| Sevelamer Carbonate | 71 | $24,519 | $345 |
| Invokana | 27 | $23,100 | $856 |
| Febuxostat | 27 | $12,961 | $480 |
| Nebivolol | 51 | $7,907 | $155 |
| Carvedilol | 212 | $3,796 | $18 |
| Amlodipine Besylate | 185 | $3,422 | $18 |
| Rosuvastatin | 38 | $3,058 | $80 |
| Tamsulosin | 52 | $2,633 | $51 |
| Valsartan | 37 | $2,578 | $70 |
| Losartan | 133 | $2,563 | $19 |
| Clonidine | 15 | $2,288 | $153 |
| Bumetanide | 41 | $1,962 | $48 |
| Allopurinol | 78 | $1,797 | $23 |
| Colchicine | 34 | $1,666 | $49 |
| Nifedipine Er | 30 | $1,470 | $49 |
| Atorvastatin | 68 | $1,387 | $20 |
| Metformin | 59 | $1,211 | $21 |
| Olmesartan Medoxomil | 39 | $1,170 | $30 |
| Furosemide | 122 | $1,129 | $9 |
| Isosorbide Mononitrate Er | 28 | $1,096 | $39 |
| Hydralazine | 44 | $1,066 | $24 |
| Potassium Chloride | 34 | $1,039 | $31 |
| Ondansetron Odt | 14 | $786 | $56 |
| Doxazosin Mesylate | 39 | $778 | $20 |
| Calcium Acetate | 25 | $692 | $28 |
| Metoprolol | 17 | $629 | $37 |
| Lisinopril | 28 | $629 | $22 |
| Chlorthalidone | 14 | $587 | $42 |
| Irbesartan | 15 | $563 | $38 |
| Glipizide | 15 | $539 | $36 |
| Benazepril | 12 | $523 | $44 |
| Calcitriol | 20 | $516 | $26 |
| Atenolol | 21 | $465 | $22 |
| Pantoprazole | 24 | $462 | $19 |
| Triamterene-Hydrochlorothiazid | 34 | $412 | $12 |
| Nitrofurantoin Mono-Macro | 13 | $402 | $31 |
| Hydrochlorothiazide | 46 | $373 | $8 |
| Finasteride | 11 | $348 | $32 |
| Metformin Hcl Er | 21 | $305 | $15 |
| Metoprolol | 16 | $295 | $18 |
| Clonidine | 12 | $196 | $16 |
| Ciprofloxacin | 17 | $193 | $11 |
| Spironolactone | 19 | $193 | $10 |
| Sure Comfort | 35 | $155 | $4 |
| Zolpidem | 18 | $42 | $2 |
2022: 51 drugs
| Farxiga | 104 | $94,016 | $904 |
| Rayaldee | 70 | $88,561 | $1,265 |
| Velphoro | 35 | $86,834 | $2,481 |
| Jardiance | 88 | $71,800 | $816 |
| Sevelamer Carbonate | 82 | $63,917 | $779 |
| Procrit | 38 | $55,347 | $1,457 |
| Lokelma | 65 | $54,197 | $834 |
| Invokana | 49 | $46,589 | $951 |
| Januvia | 34 | $34,385 | $1,011 |
| Kerendia | 20 | $23,111 | $1,156 |
| Tradjenta | 13 | $21,162 | $1,628 |
| Retacrit | 33 | $18,980 | $575 |
| Veltassa | 16 | $17,072 | $1,067 |
| Eliquis | 17 | $14,203 | $835 |
| Lanthanum Carbonate | 14 | $12,660 | $904 |
| Febuxostat | 26 | $8,045 | $309 |
| Nebivolol | 62 | $6,203 | $100 |
| Bumetanide | 38 | $2,951 | $78 |
| Calcium Acetate | 32 | $2,464 | $77 |
| Colchicine | 30 | $2,423 | $81 |
| Carvedilol | 209 | $2,134 | $10 |
| Sodium Polystyrene Sulfonate | 11 | $2,042 | $186 |
| Rosuvastatin | 67 | $1,872 | $28 |
| Losartan | 126 | $1,752 | $14 |
| Valsartan | 17 | $1,636 | $96 |
| Amlodipine Besylate | 206 | $1,407 | $7 |
| Allopurinol | 79 | $1,112 | $14 |
| Potassium Chloride | 49 | $1,019 | $21 |
| Isosorbide Mononitrate Er | 38 | $979 | $26 |
| Hydralazine | 62 | $948 | $15 |
| Furosemide | 108 | $911 | $8 |
| Tamsulosin | 62 | $825 | $13 |
| Nifedipine Er | 16 | $798 | $50 |
| Doxazosin Mesylate | 38 | $636 | $17 |
| Metformin | 55 | $547 | $10 |
| Lisinopril | 46 | $477 | $10 |
| Atorvastatin | 78 | $451 | $6 |
| Calcitriol | 16 | $375 | $23 |
| Glipizide | 21 | $362 | $17 |
| Metoprolol | 12 | $328 | $27 |
| Triamterene-Hydrochlorothiazid | 20 | $251 | $13 |
| Finasteride | 22 | $226 | $10 |
| Prednisone | 27 | $196 | $7 |
| Benazepril | 19 | $181 | $10 |
| Metformin Hcl Er | 19 | $168 | $9 |
| Metoprolol | 12 | $164 | $14 |
| Hydrochlorothiazide | 20 | $129 | $6 |
| Atenolol | 18 | $126 | $7 |
| Zolpidem | 15 | $82 | $5 |
| Clonidine | 12 | $78 | $7 |
| Ciprofloxacin | 12 | $44 | $4 |
2021: 54 drugs
| Velphoro | 46 | $123,805 | $2,691 |
| Procrit | 63 | $82,846 | $1,315 |
| Renvela | 20 | $76,341 | $3,817 |
| Invokana | 78 | $59,563 | $764 |
| Lokelma | 64 | $52,705 | $824 |
| Rayaldee | 41 | $49,710 | $1,212 |
| Sevelamer Carbonate | 89 | $45,765 | $514 |
| Jardiance | 38 | $33,844 | $891 |
| Farxiga | 44 | $31,632 | $719 |
| Tradjenta | 17 | $25,169 | $1,481 |
| Lanthanum Carbonate | 11 | $24,775 | $2,252 |
| Januvia | 20 | $19,867 | $993 |
| Veltassa | 19 | $18,674 | $983 |
| Retacrit | 30 | $18,245 | $608 |
| Eliquis | 19 | $13,357 | $703 |
| Febuxostat | 26 | $11,720 | $451 |
| Bystolic | 43 | $11,548 | $269 |
| Calcium Acetate | 19 | $2,860 | $151 |
| Colchicine | 42 | $2,753 | $66 |
| Bumetanide | 37 | $2,271 | $61 |
| Carvedilol | 189 | $1,687 | $9 |
| Losartan | 144 | $1,582 | $11 |
| Rosuvastatin | 32 | $1,333 | $42 |
| Sodium Polystyrene Sulfonate | 12 | $1,310 | $109 |
| Allopurinol | 98 | $1,247 | $13 |
| Amlodipine Besylate | 205 | $1,123 | $5 |
| Entecavir | 15 | $981 | $65 |
| Nifedipine Er | 18 | $949 | $53 |
| Valsartan | 11 | $921 | $84 |
| Potassium Chloride | 40 | $901 | $23 |
| Doxazosin Mesylate | 34 | $881 | $26 |
| Furosemide | 131 | $838 | $6 |
| Megestrol Acetate | 19 | $779 | $41 |
| Calcitriol | 20 | $749 | $37 |
| Hydralazine | 71 | $714 | $10 |
| Isosorbide Mononitrate Er | 25 | $678 | $27 |
| Metoprolol | 30 | $675 | $23 |
| Atorvastatin | 72 | $611 | $8 |
| Tamsulosin | 61 | $581 | $10 |
| Lisinopril | 38 | $329 | $9 |
| Metformin | 51 | $305 | $6 |
| Levothyroxine | 11 | $301 | $27 |
| Diclofenac | 12 | $257 | $21 |
| Metoprolol | 24 | $219 | $9 |
| Finasteride | 14 | $189 | $13 |
| Famotidine | 14 | $183 | $13 |
| Atenolol | 32 | $172 | $5 |
| Amoxicillin-Clavulanate Potass | 19 | $154 | $8 |
| Zolpidem | 17 | $153 | $9 |
| Hydrochlorothiazide | 36 | $153 | $4 |
| Triamterene-Hydrochlorothiazid | 11 | $152 | $14 |
| Glipizide | 25 | $134 | $5 |
| Metformin Hcl Er | 12 | $96 | $8 |
| Prednisone | 23 | $49 | $2 |
2020: 54 drugs
| Renvela | 26 | $75,776 | $2,914 |
| Procrit | 62 | $68,920 | $1,112 |
| Velphoro | 34 | $55,382 | $1,629 |
| Sevelamer Carbonate | 105 | $39,304 | $374 |
| Rayaldee | 29 | $32,251 | $1,112 |
| Veltassa | 29 | $25,885 | $893 |
| Tradjenta | 21 | $24,312 | $1,158 |
| Januvia | 19 | $21,789 | $1,147 |
| Invokana | 37 | $21,213 | $573 |
| Jardiance | 27 | $18,856 | $698 |
| Febuxostat | 64 | $17,792 | $278 |
| Lokelma | 18 | $15,553 | $864 |
| Bystolic | 40 | $11,947 | $299 |
| Retacrit | 22 | $9,846 | $448 |
| Eliquis | 18 | $8,819 | $490 |
| Colchicine | 35 | $5,132 | $147 |
| Colcrys | 16 | $3,184 | $199 |
| Potassium Citrate Er | 16 | $2,805 | $175 |
| Entecavir | 16 | $2,341 | $146 |
| Rosuvastatin | 33 | $2,009 | $61 |
| Novolin 70-30 | 13 | $1,886 | $145 |
| Calcium Acetate | 26 | $1,762 | $68 |
| Potassium Chloride | 45 | $1,709 | $38 |
| Isosorbide Dinitrate | 19 | $1,583 | $83 |
| Doxazosin Mesylate | 30 | $1,374 | $46 |
| Losartan | 142 | $1,347 | $9 |
| Carvedilol | 173 | $1,290 | $7 |
| Hydralazine | 87 | $1,197 | $14 |
| Bumetanide | 19 | $1,178 | $62 |
| Allopurinol | 113 | $1,009 | $9 |
| Amlodipine Besylate | 234 | $1,000 | $4 |
| Furosemide | 136 | $963 | $7 |
| Isosorbide Mononitrate Er | 44 | $925 | $21 |
| Atorvastatin | 88 | $879 | $10 |
| Metoprolol | 21 | $513 | $24 |
| Calcitriol | 13 | $459 | $35 |
| Tamsulosin | 50 | $450 | $9 |
| Minoxidil | 18 | $388 | $22 |
| Metformin | 79 | $387 | $5 |
| Fludrocortisone Acetate | 14 | $293 | $21 |
| Metoprolol | 44 | $218 | $5 |
| Enalapril Maleate | 14 | $203 | $15 |
| Lisinopril | 25 | $191 | $8 |
| Clonidine | 12 | $184 | $15 |
| Metformin Hcl Er | 15 | $168 | $11 |
| Amitriptyline | 12 | $166 | $14 |
| Hydrochlorothiazide | 42 | $158 | $4 |
| Prednisone | 16 | $155 | $10 |
| Glipizide | 35 | $122 | $3 |
| Amoxicillin-Clavulanate Potass | 13 | $106 | $8 |
| Amiloride | 13 | $78 | $6 |
| Zolpidem | 15 | $56 | $4 |
| Atenolol | 14 | $48 | $3 |
| Amoxicillin | 11 | $18 | $2 |
2019: 54 drugs
| Procrit | 70 | $68,429 | $978 |
| Velphoro | 35 | $66,862 | $1,910 |
| Veltassa | 71 | $60,315 | $850 |
| Renvela | 28 | $52,736 | $1,883 |
| Sevelamer Carbonate | 105 | $41,642 | $397 |
| Tradjenta | 47 | $32,997 | $702 |
| Januvia | 31 | $25,490 | $822 |
| Rayaldee | 15 | $17,071 | $1,138 |
| Jardiance | 23 | $15,849 | $689 |
| Uloric | 40 | $15,795 | $395 |
| Eliquis | 24 | $10,851 | $452 |
| Bystolic | 31 | $9,130 | $295 |
| Febuxostat | 23 | $9,092 | $395 |
| Epogen | 11 | $7,767 | $706 |
| Entecavir | 12 | $6,885 | $574 |
| Colchicine | 34 | $6,677 | $196 |
| Colcrys | 17 | $3,293 | $194 |
| Potassium Citrate Er | 25 | $2,415 | $97 |
| Hydralazine | 108 | $2,062 | $19 |
| Calcium Acetate | 39 | $1,752 | $45 |
| Bumetanide | 34 | $1,683 | $49 |
| Potassium Chloride | 58 | $1,572 | $27 |
| Carvedilol | 168 | $1,508 | $9 |
| Isosorbide Dinitrate | 28 | $1,496 | $53 |
| Losartan | 168 | $1,417 | $8 |
| Allopurinol | 100 | $1,360 | $14 |
| Isosorbide Mononitrate Er | 62 | $1,185 | $19 |
| Furosemide | 164 | $1,156 | $7 |
| Amlodipine Besylate | 206 | $1,065 | $5 |
| Calcitriol | 37 | $1,036 | $28 |
| Atorvastatin | 87 | $922 | $11 |
| Tamsulosin | 63 | $670 | $11 |
| Olmesartan Medoxomil | 13 | $643 | $49 |
| Clonidine | 38 | $456 | $12 |
| Fludrocortisone Acetate | 17 | $334 | $20 |
| Metoprolol | 20 | $308 | $15 |
| Enalapril Maleate | 17 | $293 | $17 |
| Triamterene-Hydrochlorothiazid | 11 | $274 | $25 |
| Metoprolol | 48 | $222 | $5 |
| Prednisone | 34 | $200 | $6 |
| Hydrochlorothiazide | 42 | $187 | $4 |
| Rosuvastatin | 17 | $184 | $11 |
| Atenolol | 25 | $169 | $7 |
| Glipizide Er | 13 | $162 | $12 |
| Lisinopril | 29 | $154 | $5 |
| Metformin | 38 | $154 | $4 |
| Warfarin | 17 | $150 | $9 |
| Digoxin | 11 | $128 | $12 |
| Metformin Hcl Er | 12 | $104 | $9 |
| Glipizide | 30 | $87 | $3 |
| Cephalexin | 12 | $81 | $7 |
| Amitriptyline | 12 | $80 | $7 |
| Levofloxacin | 16 | $59 | $4 |
| Zolpidem | 14 | $45 | $3 |
2018: 56 drugs
| Renvela | 86 | $127,133 | $1,478 |
| Procrit | 102 | $80,505 | $789 |
| Sevelamer Carbonate | 49 | $38,385 | $783 |
| Veltassa | 29 | $29,810 | $1,028 |
| Tradjenta | 50 | $28,926 | $579 |
| Uloric | 54 | $23,996 | $444 |
| Lanthanum Carbonate | 14 | $22,740 | $1,624 |
| Sensipar | 24 | $21,831 | $910 |
| Januvia | 22 | $18,322 | $833 |
| Bystolic | 51 | $10,892 | $214 |
| Jardiance | 22 | $10,602 | $482 |
| Eliquis | 19 | $6,887 | $362 |
| Colchicine | 28 | $5,820 | $208 |
| Clinisol | 29 | $2,745 | $95 |
| Colcrys | 14 | $2,733 | $195 |
| Calcium Acetate | 34 | $2,071 | $61 |
| Potassium Chloride | 65 | $1,894 | $29 |
| Omega-3 Acid Ethyl Esters | 12 | $1,778 | $148 |
| Prosol | 21 | $1,634 | $78 |
| Midodrine | 28 | $1,590 | $57 |
| Allopurinol | 114 | $1,528 | $13 |
| Potassium Citrate Er | 16 | $1,495 | $93 |
| Hydralazine | 104 | $1,486 | $14 |
| Bumetanide | 27 | $1,469 | $54 |
| Losartan | 252 | $1,287 | $5 |
| Atorvastatin | 90 | $1,097 | $12 |
| Calcitriol | 54 | $1,093 | $20 |
| Carvedilol | 179 | $1,025 | $6 |
| Amlodipine Besylate | 207 | $893 | $4 |
| Isosorbide Mononitrate Er | 31 | $777 | $25 |
| Ezetimibe | 11 | $764 | $69 |
| Furosemide | 141 | $734 | $5 |
| Tamsulosin | 57 | $656 | $12 |
| Nifedipine Er | 13 | $645 | $50 |
| Valsartan | 12 | $588 | $49 |
| Verapamil Er | 14 | $544 | $39 |
| Clonidine | 59 | $362 | $6 |
| Fludrocortisone Acetate | 16 | $337 | $21 |
| Metoprolol | 18 | $326 | $18 |
| Enalapril Maleate | 17 | $318 | $19 |
| Atenolol | 50 | $282 | $6 |
| Prednisone | 37 | $263 | $7 |
| Metoprolol | 61 | $219 | $4 |
| Triamterene-Hydrochlorothiazid | 14 | $218 | $16 |
| Hydrochlorothiazide | 55 | $204 | $4 |
| Digoxin | 12 | $196 | $16 |
| Pioglitazone | 11 | $135 | $12 |
| Levofloxacin | 18 | $133 | $7 |
| Metformin | 32 | $121 | $4 |
| Omeprazole | 21 | $121 | $6 |
| Lisinopril | 32 | $114 | $4 |
| Simvastatin | 23 | $106 | $5 |
| Losartan-Hydrochlorothiazide | 17 | $106 | $6 |
| Gemfibrozil | 11 | $100 | $9 |
| Clopidogrel | 14 | $90 | $6 |
| Glipizide | 14 | $51 | $4 |
2017: 56 drugs
| Renvela | 118 | $183,547 | $1,555 |
| Sensipar | 144 | $181,318 | $1,259 |
| Procrit | 59 | $50,209 | $851 |
| Veltassa | 22 | $26,158 | $1,189 |
| Uloric | 69 | $26,083 | $378 |
| Januvia | 43 | $24,918 | $579 |
| Fosrenol | 12 | $22,875 | $1,906 |
| Tradjenta | 48 | $21,435 | $447 |
| Bystolic | 60 | $9,388 | $156 |
| Colchicine | 34 | $6,313 | $186 |
| Colcrys | 22 | $4,570 | $208 |
| Calcium Acetate | 40 | $2,882 | $72 |
| Bumetanide | 28 | $1,837 | $66 |
| Allopurinol | 139 | $1,834 | $13 |
| Omega-3 Acid Ethyl Esters | 16 | $1,789 | $112 |
| Calcitriol | 93 | $1,699 | $18 |
| Potassium Chloride | 46 | $1,484 | $32 |
| Nifedipine Er | 17 | $1,444 | $85 |
| Verapamil | 11 | $1,338 | $122 |
| Potassium Citrate Er | 13 | $1,332 | $102 |
| Atorvastatin | 111 | $1,285 | $12 |
| Doxazosin Mesylate | 16 | $1,129 | $71 |
| Valsartan | 31 | $1,126 | $36 |
| Amlodipine Besylate | 189 | $829 | $4 |
| Losartan | 164 | $800 | $5 |
| Hydralazine | 67 | $795 | $12 |
| Mycophenolate Mofetil | 12 | $682 | $57 |
| Carvedilol | 95 | $553 | $6 |
| Tamsulosin | 33 | $503 | $15 |
| Furosemide | 138 | $412 | $3 |
| Insulin | 12 | $402 | $34 |
| Lisinopril | 52 | $388 | $7 |
| Fludrocortisone Acetate | 17 | $366 | $22 |
| Enalapril Maleate | 16 | $322 | $20 |
| Zolpidem | 22 | $297 | $13 |
| Metoprolol | 69 | $244 | $4 |
| Pioglitazone | 21 | $237 | $11 |
| Prednisone | 40 | $224 | $6 |
| Triamterene-Hydrochlorothiazid | 16 | $194 | $12 |
| Hydrochlorothiazide | 49 | $188 | $4 |
| Hydroxyzine | 18 | $183 | $10 |
| Atenolol | 37 | $178 | $5 |
| Clopidogrel | 25 | $172 | $7 |
| Metoprolol | 12 | $150 | $13 |
| Clonidine | 39 | $147 | $4 |
| Glipizide | 29 | $146 | $5 |
| Simvastatin | 21 | $145 | $7 |
| Klor-Con 10 | 17 | $144 | $8 |
| Glipizide Er | 13 | $136 | $10 |
| Spironolactone | 19 | $122 | $6 |
| Diltiazem 24hr Er | 12 | $101 | $8 |
| Gemfibrozil | 13 | $98 | $8 |
| Famotidine | 24 | $92 | $4 |
| Metformin | 21 | $84 | $4 |
| Omeprazole | 13 | $69 | $5 |
| Losartan-Hydrochlorothiazide | 12 | $57 | $5 |
2016: 51 drugs
| Renvela | 106 | $164,440 | $1,551 |
| Sensipar | 100 | $137,571 | $1,376 |
| Fosrenol | 19 | $33,937 | $1,786 |
| Uloric | 79 | $24,565 | $311 |
| Januvia | 39 | $24,019 | $616 |
| Tradjenta | 50 | $21,425 | $429 |
| Colchicine | 43 | $6,883 | $160 |
| Colcrys | 27 | $5,828 | $216 |
| Lantus | 14 | $3,579 | $256 |
| Clobetasol Propionate | 12 | $3,549 | $296 |
| Novolog | 13 | $3,311 | $255 |
| Calcium Acetate | 36 | $2,734 | $76 |
| Potassium Chloride | 78 | $2,054 | $26 |
| Bumetanide | 40 | $1,741 | $44 |
| Allopurinol | 148 | $1,705 | $12 |
| Bystolic | 15 | $1,639 | $109 |
| Atorvastatin | 98 | $1,348 | $14 |
| Doxazosin Mesylate | 22 | $1,266 | $58 |
| Amlodipine Besylate | 215 | $1,124 | $5 |
| Midodrine | 16 | $968 | $60 |
| Calcitriol | 44 | $965 | $22 |
| Nifedipine Er | 17 | $899 | $53 |
| Valsartan | 14 | $888 | $63 |
| Losartan | 129 | $799 | $6 |
| Furosemide | 187 | $651 | $3 |
| Hydralazine | 33 | $544 | $16 |
| Labetalol | 11 | $435 | $40 |
| Tamsulosin | 19 | $416 | $22 |
| Carvedilol | 61 | $406 | $7 |
| Zolpidem | 16 | $309 | $19 |
| Pravastatin | 21 | $278 | $13 |
| Metoprolol | 72 | $272 | $4 |
| Fludrocortisone Acetate | 15 | $269 | $18 |
| Ranitidine | 11 | $254 | $23 |
| Enalapril Maleate | 15 | $225 | $15 |
| Clonidine | 43 | $221 | $5 |
| Klor-Con 10 | 18 | $218 | $12 |
| Metoprolol | 15 | $215 | $14 |
| Hydrochlorothiazide | 40 | $191 | $5 |
| Lisinopril | 53 | $181 | $3 |
| Spironolactone | 15 | $180 | $12 |
| Glipizide | 34 | $161 | $5 |
| Simvastatin | 37 | $139 | $4 |
| Amitriptyline | 11 | $136 | $12 |
| Atenolol | 45 | $129 | $3 |
| Triamterene-Hydrochlorothiazid | 11 | $126 | $11 |
| Gemfibrozil | 13 | $105 | $8 |
| Glipizide Xl | 12 | $103 | $9 |
| Omeprazole | 19 | $89 | $5 |
| Benazepril | 14 | $82 | $6 |
| Losartan-Hydrochlorothiazide | 21 | $80 | $4 |
2015: 57 drugs
| Renvela | 89 | $142,321 | $1,599 |
| Sensipar | 90 | $103,992 | $1,155 |
| Fosrenol | 16 | $23,108 | $1,444 |
| Xifaxan | 17 | $19,753 | $1,162 |
| Tradjenta | 37 | $15,030 | $406 |
| Januvia | 26 | $13,437 | $517 |
| Uloric | 29 | $10,456 | $361 |
| Colcrys | 48 | $9,034 | $188 |
| Lantus | 22 | $7,559 | $344 |
| Zetia | 26 | $6,782 | $261 |
| Calcium Acetate | 53 | $6,172 | $116 |
| Colchicine | 28 | $4,476 | $160 |
| Clobetasol Propionate | 11 | $3,304 | $300 |
| Novolog | 12 | $2,715 | $226 |
| Potassium Chloride | 60 | $2,098 | $35 |
| Allopurinol | 155 | $1,813 | $12 |
| Bystolic | 14 | $1,806 | $129 |
| Midodrine | 25 | $1,516 | $61 |
| Amlodipine Besylate | 278 | $1,256 | $5 |
| Potassium Citrate Er | 13 | $1,205 | $93 |
| Sodium Polystyrene Sulfonate | 11 | $1,131 | $103 |
| Doxazosin Mesylate | 13 | $1,090 | $84 |
| Tamsulosin | 26 | $1,005 | $39 |
| Calcitriol | 31 | $877 | $28 |
| Nifedipine Er | 20 | $854 | $43 |
| Atorvastatin | 68 | $784 | $12 |
| Losartan | 118 | $775 | $7 |
| Furosemide | 181 | $620 | $3 |
| Pioglitazone | 15 | $522 | $35 |
| Megestrol Acetate | 20 | $413 | $21 |
| Hydralazine | 18 | $370 | $21 |
| Fludrocortisone Acetate | 16 | $361 | $23 |
| Clonidine | 36 | $311 | $9 |
| Simvastatin | 59 | $307 | $5 |
| Pravastatin | 13 | $300 | $23 |
| Metoprolol | 68 | $281 | $4 |
| Zolpidem | 16 | $281 | $18 |
| Ranitidine | 11 | $275 | $25 |
| Metoprolol | 16 | $237 | $15 |
| Carvedilol | 48 | $211 | $4 |
| Insulin | 13 | $206 | $16 |
| Hydrochlorothiazide | 41 | $195 | $5 |
| Lisinopril | 39 | $162 | $4 |
| Spironolactone | 12 | $160 | $13 |
| Triamterene-Hydrochlorothiazid | 13 | $156 | $12 |
| Klor-Con 10 | 12 | $125 | $10 |
| Amitriptyline | 11 | $120 | $11 |
| Omeprazole | 17 | $115 | $7 |
| Glipizide | 29 | $107 | $4 |
| Losartan-Hydrochlorothiazide | 23 | $103 | $4 |
| Prednisone | 13 | $84 | $6 |
| Gabapentin | 12 | $82 | $7 |
| Atenolol | 26 | $82 | $3 |
| Glipizide Xl | 11 | $61 | $6 |
| Benazepril | 11 | $48 | $4 |
| Famotidine | 13 | $32 | $2 |
| Clonazepam | 11 | $31 | $3 |
2014: 54 drugs
| Renvela | 114 | $128,338 | $1,126 |
| Sensipar | 86 | $84,956 | $988 |
| Fosrenol | 21 | $36,224 | $1,725 |
| Januvia | 53 | $19,627 | $370 |
| Xifaxan | 11 | $15,347 | $1,395 |
| Colcrys | 73 | $12,073 | $165 |
| Uloric | 36 | $10,532 | $293 |
| Sevelamer Carbonate | 18 | $9,387 | $522 |
| Calcium Acetate | 49 | $8,314 | $170 |
| Zetia | 14 | $4,094 | $292 |
| Lantus | 16 | $3,971 | $248 |
| Midodrine | 32 | $3,295 | $103 |
| Novolog | 16 | $2,958 | $185 |
| Premarin | 12 | $2,572 | $214 |
| Nifedipine Er | 29 | $2,187 | $75 |
| Hydralazine | 63 | $1,842 | $29 |
| Kionex | 18 | $1,821 | $101 |
| Amlodipine Besylate | 291 | $1,772 | $6 |
| Clobetasol Propionate | 12 | $1,558 | $130 |
| Potassium Chloride | 62 | $1,496 | $24 |
| Atorvastatin | 69 | $1,360 | $20 |
| Losartan | 141 | $1,243 | $9 |
| Doxazosin Mesylate | 13 | $963 | $74 |
| Megestrol Acetate | 29 | $942 | $32 |
| Calcitriol | 35 | $933 | $27 |
| Allopurinol | 121 | $861 | $7 |
| Mycophenolate Mofetil | 17 | $830 | $49 |
| Furosemide | 158 | $755 | $5 |
| Pravastatin | 31 | $715 | $23 |
| Clonidine | 43 | $711 | $17 |
| Pioglitazone | 16 | $612 | $38 |
| Verapamil | 11 | $533 | $48 |
| Metoprolol | 19 | $508 | $27 |
| Simvastatin | 60 | $450 | $7 |
| Metoprolol | 72 | $421 | $6 |
| Diltiazem Er | 14 | $401 | $29 |
| Tamsulosin | 23 | $365 | $16 |
| Diltiazem 24hr Er | 17 | $342 | $20 |
| Losartan-Hydrochlorothiazide | 21 | $294 | $14 |
| Fludrocortisone Acetate | 11 | $291 | $26 |
| Carvedilol | 25 | $281 | $11 |
| Atenolol | 41 | $240 | $6 |
| Hydrochlorothiazide | 48 | $222 | $5 |
| Triamterene-Hydrochlorothiazid | 19 | $220 | $12 |
| Hydrocodone-Acetaminophen | 11 | $203 | $18 |
| Lisinopril | 35 | $175 | $5 |
| Glipizide | 41 | $147 | $4 |
| Gabapentin | 19 | $134 | $7 |
| Warfarin | 15 | $102 | $7 |
| Zolpidem | 16 | $98 | $6 |
| Clopidogrel | 12 | $79 | $7 |
| Famotidine | 16 | $68 | $4 |
| Cephalexin | 11 | $62 | $6 |
| Clonazepam | 11 | $36 | $3 |
2013: 51 drugs
| Renvela | 107 | $92,552 | $865 |
| Sensipar | 96 | $71,887 | $749 |
| Prosol | 113 | $25,518 | $226 |
| Fosrenol | 15 | $17,925 | $1,195 |
| Januvia | 65 | $17,611 | $271 |
| Uloric | 50 | $11,994 | $240 |
| Colcrys | 54 | $8,076 | $150 |
| Calcium Acetate | 53 | $6,667 | $126 |
| Diovan | 25 | $4,891 | $196 |
| Nexium | 12 | $4,188 | $349 |
| Lantus | 17 | $2,563 | $151 |
| Kionex | 26 | $2,551 | $98 |
| Dextrose in Water | 49 | $2,415 | $49 |
| Amlodipine Besylate | 284 | $2,253 | $8 |
| Hydralazine | 67 | $2,015 | $30 |
| Calcitriol | 65 | $1,895 | $29 |
| Novolog | 12 | $1,869 | $156 |
| Pioglitazone | 23 | $1,857 | $81 |
| Midodrine | 17 | $1,853 | $109 |
| Nifedipine Er | 24 | $1,654 | $69 |
| Atorvastatin | 58 | $1,530 | $26 |
| Losartan | 110 | $1,479 | $13 |
| Mycophenolate Mofetil | 20 | $1,239 | $62 |
| Lovaza | 11 | $1,141 | $104 |
| Nifedical Xl | 17 | $1,089 | $64 |
| Carvedilol | 86 | $1,071 | $12 |
| Isosorbide Dinitrate | 15 | $1,045 | $70 |
| Megestrol Acetate | 22 | $796 | $36 |
| Simvastatin | 84 | $725 | $9 |
| Pravastatin | 47 | $691 | $15 |
| Potassium Chloride | 37 | $670 | $18 |
| Allopurinol | 110 | $669 | $6 |
| Clonidine | 41 | $573 | $14 |
| Furosemide | 126 | $564 | $4 |
| Doxazosin Mesylate | 14 | $485 | $35 |
| Diltiazem 24hr Er | 20 | $484 | $24 |
| Amiodarone | 14 | $392 | $28 |
| Tamsulosin | 21 | $387 | $18 |
| Glyburide | 17 | $333 | $20 |
| Lisinopril | 59 | $331 | $6 |
| Metoprolol | 51 | $327 | $6 |
| Gabapentin | 19 | $225 | $12 |
| Losartan-Hydrochlorothiazide | 13 | $222 | $17 |
| Zolpidem | 33 | $217 | $7 |
| Famotidine | 24 | $159 | $7 |
| Hydrochlorothiazide | 22 | $156 | $7 |
| Atenolol | 25 | $139 | $6 |
| Glipizide | 21 | $138 | $7 |
| Azithromycin | 11 | $126 | $11 |
| Triamterene-Hctz | 11 | $111 | $10 |
| Prednisone | 14 | $54 | $4 |
Money from drug and device companies
$2,082 in 2025
| 2025 | 16 | 74 | None | $2,082 |
| 2024 | 17 | 68 | $2,984 | $4,693 |
| 2023 | 17 | 115 | None | $2,271 |
| 2022 | 12 | 44 | None | $798 |
| 2021 | 4 | 11 | $600 | $790 |
| 2020 | 6 | 18 | None | $365 |
| 2019 | 6 | 9 | None | $249 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Otsuka America Pharmaceutical | Jynarque | $310 | 8 payments
|
| Amgen | Krystexxa | $296 | 11 payments
|
| Mallinckrodt Hospital Products | Acthar | $247 | 9 payments
|
| Fresenius USA Marketing | Velphoro | $212 | 9 payments
|
| Travere Therapeutics | None | $179 | 6 payments
|
| ANI Pharmaceuticals | Purified Cortrophin Gel | $167 | 6 payments
|
See all 74 published payments
| Amgen | Meals · 2025-12-22 | Tavneos | $17 |
| Fresenius USA Marketing | Meals · 2025-12-18 | Velphoro | $24 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-16 | Farxiga | $34 |
| Fresenius USA Marketing | Meals · 2025-12-10 | Velphoro | $25 |
| ANI Pharmaceuticals | Meals · 2025-12-10 | Purified Cortrophin Gel | $27 |
| Otsuka America Pharmaceutical | Meals · 2025-12-09 | Jynarque | $28 |
| ANI Pharmaceuticals | Meals · 2025-12-08 | Purified Cortrophin Gel | $33 |
| Mallinckrodt Hospital Products | Meals · 2025-11-22 | Acthar | $30 |
| ANI Pharmaceuticals | Meals · 2025-11-21 | Purified Cortrophin Gel | $23 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-20 | Farxiga | $24 |
| Amgen | Meals · 2025-11-17 | Krystexxa | $21 |
| Amgen | Meals · 2025-11-13 | Krystexxa | $33 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-11-12 | Jardiance | $34 |
| Novartis Pharmaceuticals | Meals · 2025-10-31 | Fabhalta | $28 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-31 | Farxiga | $26 |
| ANI Pharmaceuticals | Meals · 2025-10-29 | Purified Cortrophin Gel | $34 |
| Apellis Pharmaceuticals | Meals · 2025-10-25 | Empaveli | $27 |
| Amgen | Meals · 2025-10-23 | Tavneos | $30 |
| Travere Therapeutics | Meals · 2025-10-17 | None | $38 |
| Novo Nordisk | Meals · 2025-10-09 | Wegovy | $15 |
| Otsuka America Pharmaceutical | Meals · 2025-10-07 | Jynarque | $26 |
| Lilly USA | Meals · 2025-09-27 | Jardiance | $31 |
| Novo Nordisk | Meals · 2025-09-16 | Wegovy | $16 |
| Mallinckrodt Hospital Products | Meals · 2025-09-13 | Acthar | $37 |
| Amgen | Meals · 2025-09-10 | Krystexxa | $28 |
| Otsuka America Pharmaceutical | Meals · 2025-09-09 | Jynarque | $20 |
| ANI Pharmaceuticals | Meals · 2025-09-08 | Purified Cortrophin Gel | $18 |
| Travere Therapeutics | Meals · 2025-09-05 | None | $30 |
| Calliditas Therapeutics US | Meals · 2025-08-28 | Tarpeyo | $35 |
| Lilly USA | Meals · 2025-08-20 | Jardiance | $31 |
| Mallinckrodt Hospital Products | Meals · 2025-08-16 | Acthar | $13 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-08-14 | Jardiance | $27 |
| NxStage Medical | Meals · 2025-08-13 | Nxstage System One | $25 |
| Travere Therapeutics | Meals · 2025-08-13 | None | $27 |
| Otsuka America Pharmaceutical | Meals · 2025-08-11 | Jynarque | $32 |
| Travere Therapeutics | Meals · 2025-08-08 | None | $34 |
| Fresenius USA Marketing | Meals · 2025-07-25 | Velphoro | $24 |
| Novo Nordisk | Meals · 2025-07-24 | Wegovy | $26 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-07-24 | Jardiance | $30 |
| Amgen | Meals · 2025-07-21 | Krystexxa | $21 |
| Amgen | Meals · 2025-07-14 | Tavneos | $33 |
| Otsuka America Pharmaceutical | Meals · 2025-07-10 | Jynarque | $26 |
| ANI Pharmaceuticals | Meals · 2025-06-30 | Purified Cortrophin Gel | $32 |
| Mallinckrodt Hospital Products | Meals · 2025-06-28 | Acthar | $31 |
| Lilly USA | Meals · 2025-06-06 | Jardiance | $25 |
| Mallinckrodt Hospital Products | Meals · 2025-05-29 | Acthar | $35 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-17 | Farxiga | $28 |
| Novartis Pharmaceuticals | Meals · 2025-05-12 | Fabhalta | $31 |
| Amgen | Meals · 2025-05-09 | Krystexxa | $23 |
| Otsuka America Pharmaceutical | Meals · 2025-05-08 | Jynarque | $28 |
| Novo Nordisk | Meals · 2025-05-07 | Ozempic | $32 |
| Calliditas Therapeutics US | Meals · 2025-05-05 | Tarpeyo | $27 |
| Mallinckrodt Hospital Products | Meals · 2025-05-02 | Acthar | $8 |
| Fresenius USA Marketing | Meals · 2025-04-30 | Velphoro | $24 |
| Otsuka America Pharmaceutical | Meals · 2025-04-22 | Jynarque | $124 |
| Fresenius USA Marketing | Meals · 2025-04-18 | Velphoro | $23 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-15 | Farxiga | $26 |
| Fresenius USA Marketing | Meals · 2025-04-11 | Velphoro | $23 |
| Travere Therapeutics | Meals · 2025-03-21 | None | $23 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-03-20 | Jardiance | $33 |
| Fresenius USA Marketing | Meals · 2025-03-14 | Velphoro | $24 |
| Otsuka Pharmaceutical Development & Commercialization | Meals · 2025-03-10 | None | $25 |
| Amgen | Meals · 2025-03-05 | Krystexxa | $31 |
| Mallinckrodt Hospital Products | Meals · 2025-03-04 | Acthar | $30 |
| Fresenius USA Marketing | Meals · 2025-02-26 | Velphoro | $22 |
| Mallinckrodt Hospital Products | Meals · 2025-02-12 | Acthar | $29 |
| Novo Nordisk | Meals · 2025-02-11 | Ozempic | $14 |
| Mallinckrodt Hospital Products | Meals · 2025-02-06 | Acthar | $35 |
| Travere Therapeutics | Meals · 2025-02-03 | None | $28 |
| Amgen | Meals · 2025-01-30 | Tavneos | $34 |
| OPKO Pharmaceuticals | Education · 2025-01-29 | Rayaldee | $21 |
| Amgen | Meals · 2025-01-27 | Krystexxa | $25 |
| Otsuka America Pharmaceutical | Meals · 2025-01-24 | Jynarque | $26 |
| Fresenius USA Marketing | Meals · 2025-01-08 | Velphoro | $24 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $4,693
| Otsuka Pharmaceutical Development & Commercialization | None | $3,210 | 6 payments
|
| Amgen | Krystexxa | $277 | 12 payments
|
| Fresenius USA Marketing | Velphoro | $180 | 9 payments
|
| Otsuka America Pharmaceutical | Jynarque | $172 | 4 payments
|
| Lilly USA | Jardiance | $129 | 4 payments
|
| Novo Nordisk | Ozempic | $104 | 6 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $97 | 5 payments
|
| Calliditas Therapeutics US | Tarpeyo | $87 | 4 payments
|
| Ardelyx | Ibsrela | $87 | 3 payments
|
| Travere Therapeutics | None | $67 | 4 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $64 | 3 payments
|
| Aurinia Pharma U.S. | Lupkynis | $52 | 2 payments
|
| Novartis Pharmaceuticals | Fabhalta | $47 | 2 payments
|
| GlaxoSmithKline | Jesduvroq | $35 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $32 | 1 payment
|
| Mallinckrodt Hospital Products | Acthar | $30 | 1 payment
|
| OPKO Pharmaceuticals | Rayaldee | $22 | 1 payment
|
2023: $2,271
| AstraZeneca Pharmaceuticals LP | Farxiga | $475 | 19 payments
|
| Fresenius USA Marketing | Velphoro | $390 | 27 payments
|
| Travere Therapeutics | None | $288 | 19 payments
|
| Otsuka America Pharmaceutical | Jynarque | $185 | 7 payments
|
| Horizon Therapeutics plc | Krystexxa | $165 | 12 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $142 | 6 payments
|
| GlaxoSmithKline | Arexvy | $134 | 3 payments
|
| Lilly USA | Mounjaro | $120 | 1 payment
|
| Calliditas Therapeutics US | Tarpeyo | $60 | 2 payments
|
| Novo Nordisk | Rybelsus | $54 | 3 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $53 | 2 payments
|
| Novartis Pharmaceuticals | None | $47 | 2 payments
|
| Aurinia Pharma U.S. | Lupkynis | $45 | 2 payments
|
| Alexion Pharmaceuticals | Ultomiris | $31 | 1 payment
|
| Otsuka Pharmaceutical Development & Commercialization | Jynarque | $29 | 1 payment
|
| Genzyme | Fabrazyme | $25 | 1 payment
|
| OPKO Pharmaceuticals | Rayaldee | $25 | 1 payment
|
2022: $798
| Otsuka America Pharmaceutical | Jynarque | $320 | 16 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $216 | 9 payments
|
| Otsuka Pharmaceutical Development & Commercialization | Jynarque | $48 | 2 payments
|
| OPKO Pharmaceuticals | Rayaldee | $32 | 2 payments
|
| Daiichi Sankyo | Injectafer | $27 | 1 payment
|
| Travere Therapeutics | None | $25 | 1 payment
|
| Fresenius USA Marketing | Velphoro | $24 | 1 payment
|
| GlaxoSmithKline | Benlysta | $24 | 1 payment
|
| Vifor Pharma | Veltassa | $23 | 1 payment
|
| Calliditas Therapeutics US | Tarpeyo | $21 | 1 payment
|
| Horizon Therapeutics plc | Krystexxa | $20 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $17 | 1 payment
|
2021: $790
| Genzyme | Cablivi | $400 | 1 payment
|
| Vifor Pharma | Veltassa | $200 | 1 payment
|
| Otsuka America Pharmaceutical | Jynarque | $164 | 8 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $27 | 1 payment
|
2020: $365
| AstraZeneca Pharmaceuticals LP | Lokelma | $134 | 6 payments
|
| Otsuka America Pharmaceutical | Jynarque | $118 | 6 payments
|
| Relypsa | Veltassa | $44 | 2 payments
|
| Akebia Therapeutics | Auryxia | $39 | 2 payments
|
| Amgen | Parsabiv | $18 | 1 payment
|
| Daiichi Sankyo | Injectafer | $13 | 1 payment
|
2019: $249
| Alexion Pharmaceuticals | None | $115 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $44 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Lokelma | $30 | 2 payments
|
| Relypsa | Veltassa | $24 | 1 payment
|
| Daiichi Sankyo | Injectafer | $23 | 2 payments
|
| Fresenius USA Marketing | Velphoro | $12 | 1 payment
|
Professional record
- NPI
- 1306959135
- Licence
- CA A70467California A70467: Current · expires 2027-10-31
- Trained
- Albert Einstein College of Medicine of Yeshiva University, 1995 · 31 years ago
- Group
- West Coast Kidney
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A704670
- Taxonomy
- Federal specialty code 207RN0300X (207RN0300X); Federal specialty code 174400000X (174400000X)
- Mailing address
- 3300 Webster St, Suite 304, Oakland, CA, 94609
- NPI first listed
- 2006-08-16
- NPI last updated
- 2024-01-04
- NPI record certified
- 2024-01-04
This is when the NPI record was last certified, not a medical board exam.